Biogen Inc. stock underperforms Wednesday when compared to competitors
Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...
TD Cowen Remains a Buy on Biogen (BIIB)
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed
Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...
Decoding Biogen's Options Activity: What's the Big Picture?
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
Biogen announces initiation of dosing in TRANSCEND
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)
Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug
The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...
Mena FN3h
Multiple Sclerosis Therapeutics Market Projected To Witness Substantial Growth, 2025-2032: Biogen Inc., Novartis AG
Multiple Sclerosis Therapeutics market is estimated to be valued at USD 31.39 Bn in 2025 and is expected to reach USD 41.89 Bn by 2032, exhibiting a CAGR of 4%. BURLINGAME, CA, UNITED STATES, March 13 ...